Citigroup Inc Regeneron Pharmaceuticals, Inc. Put Options Transaction History

Citigroup Inc

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 10, 2024	SELL	$902.69 - $993.35 $33 Million - $36.4 Million	-36,600 Reduced 46.86%	41,500 $39.9 Million
Q4 2023 Feb 09, 2024	SELL	$775.18 - $881.7 $27 Million - $30.7 Million	-34,800 Reduced 30.82%	78,100 $68.6 Million
Q3 2023 Nov 09, 2023	BUY	$692.45 - $844.37 $42 Million - $51.3 Million	60,700 Added 116.28%	112,900 $92.9 Million
Q2 2023 Aug 10, 2023	BUY	$700.03 - $830.35 $17.3 Million - $20.5 Million	24,700 Added 89.82%	52,200 $37.5 Million
Q1 2023 May 11, 2023	BUY	$680.49 - $826.97 $9.19 Million - $11.2 Million	13,500 Added 96.43%	27,500 $22.6 Million

Q4 2022 Feb 09, 2023	SELL	$705.89 - $766.39 $7.06 Million - $7.66 Million	-10,000 Reduced 41.67%	14,000 $10.1 Million
Q3 2022 Nov 10, 2022	BUY	$573.97 - $724.32 $5.74 Million - $7.24 Million	10,000 Added 71.43%	24,000 $16.5 Million
Q1 2022 May 12, 2022	SELL	$595.12 - $698.43 $15.8 Million - $18.5 Million	-26,500 Reduced 65.43%	14,000 $9.78 Million
Q3 2021 Nov 10, 2021	BUY	$574.03 - $680.96 $23.2 Million - $27.6 Million	40,500 New	40,500 $24.5 Million

1,424

82.1M

835K

1.46M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $113B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.